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Objective: To evaluate the early outcomes of patients undergoing thoracic endovascular aortic repair for blunt thoracic
aortic injuries.
Methods: A prospective, nonrandomized, multicenter trial using the Medtronic Valiant Captivia stent graft was
conducted at 20 sites in North America. Fifty patients with blunt thoracic aortic injuries were enrolled between
April 2010 and January 2012 and will be followed for 5 years. The injuries were classiﬁed into categories (grades
I-IV) based on severity: intimal tear, intramural hematoma, pseudoaneurysm, or rupture. The primary end point
was 30-day all-cause mortality. Secondary end points were adverse events occurring within 30 days that were related
to the procedure, device or aorta, and aortic-related mortality. Technical success was measured as successful device
delivery and deployment.
Results: Seventy-six percent (38/50) of patients were male with mean age of 41 6 17 years. Fifty-one Medtronic Valiant
Captivia thoracic stent grafts and a single Talent thoracic stent graft were implanted within a median of 1.0 days
following injury (mean, 1.8 6 4.0 days). Seventy percent (35/50) of aortic injuries were grade III or higher, including
one patient with free rupture. Mean injury severity score was 38 6 14. Fifty-four percent of stent grafts were #26 mm
(28/52). The left subclavian artery was completely covered in 40% of patients (20/50) and partially covered in 18% of
patients (9/50). Four patients underwent subclavian artery revascularization: one at the time of the endograft procedure
and three others after developing arm ischemia after the initial endograft procedure. Cerebral spinal ﬂuid was drained in
two patients. The median procedure time was 91 minutes, and median hospital stay was 12 days. There was 100%
successful device delivery and deployment. Four (8%) patients died within 30 days. Nonfatal adverse events within 30 days
that were related to the procedure, device, or aorta were experienced by 12% (6/50) of patients. No nonfatal adverse
events related to the device were reported; a single death was conservatively adjudicated as device-, procedure-, and aorta-
related because of insufﬁcient information. No patient developed spinal cord injury, and there were no cerebrovascular
accidents. However, one patient had an anoxic brain injury following aortic rupture. No patient underwent conversion to
open repair or required an endovascular reintervention.
Conclusions: Based on the early outcomes, the Medtronic Valiant Captivia stent graft appears to be a promising treatment
modality for blunt thoracic aortic injuries. Long-term follow-up is necessary to substantiate the effectiveness of thoracic
endovascular aortic repair in treatment of blunt thoracic aortic injuries. (J Vasc Surg 2013;57:899-905.)Blunt thoracic aortic injury (BTAI) remains the second of deaths occurring at the scene.4 Based on a report from
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900 Khoynezhad et al April 2013patient population. The advantages of TEVAR include
reducing the morbidity and adverse effects of cardiopulmo-
nary bypass such as signiﬁcant systemic heparinization,
paraplegia, and performance of a thoracotomy. Multiple
studies3,6-15 and meta-analyses16-19 have documented
favorable early outcomes with TEVAR compared with
the traditional open surgical approach for BTAI. TEVAR
may be performed as a bridging or deﬁnitive therapy,
allowing stabilization of the patient so that competing
traumatic injuries can be treated.
The aim of the Clinical PeRformancE of the Valiant
Thoracic Stent Graft with the Captivia Delivery System for
the EndovaSCUlar trEatment of Blunt Thoracic Aortic
Injuries (RESCUE) trial is to capture the 30-day and
5-year outcomes of TEVAR using the Medtronic Valiant
Captivia stent graft (Medtronic Vascular, Santa Rosa, Calif),
a Food and Drug Administration (FDA)-approved stent
graft for aneurysmal indications, in patients with BTAI.
METHODS
A prospective, nonrandomized, multicenter trial using
the Medtronic Valiant Captivia stent graft (Medtronic,
Inc)19 was conducted at 20 sites in North America
(NCT# 01092767). Fifty patients underwent TEVAR for
BTAI between April 2010 and January 2012; a total of
69 patients were screened using established inclusion and
exclusion criteria (see below). The primary end point was
all-cause mortality within 30 days. Secondary end points
were nonfatal adverse events occurring within 30 days
that were related to the procedure, device or aorta, and
aortic-related mortality. Technical success, measured as
successful device delivery and deployment, was also re-
ported. Patients will be followed for 5 years.
All imaging was provided to an independent core
laboratory for analysis of stent graft fracture, twisting,
and kinking, loss of patency, and migration > 10 mm
(M2S, Inc; West Lebanon, NH). All deaths were adjudi-
cated by a Clinical Events Committee (CEC) coordinated
by Harvard Clinical Research Institute (Boston, Mass).
Harvard Clinical Research Institute also coordinated an
independent data monitoring committee, which reviewed
all adverse events associated with a death during the
conduct of the study. Relatedness for nonfatal adverse
events was determined by the investigator. All source docu-
ments were monitored and queries issued regarding any
additional potential related events.
Inclusion criteria. The patients were evaluated by
preoperative computed tomographic angiography (CTA)
for BTAI. The aortic injury was conﬁrmed at the time of
repair using angiography or intravascular ultrasound.
Enrolled patients were at least 18 years old and underwent
TEVAR within 30 days of injury. Informed consent was
obtained for all procedures, offered through an Investiga-
tional Device Exemption (IDE) approved by the U.S.
FDA (IDE# G090201) or an Investigational Testing
Authorisation (IST) approved by Health Canada (IST#
171559). Anatomic enrollment criteria included aortic
diameter (adventitia to adventitia) of the proximal anddistal landing zones between 18 and 44 mm, adequate
diameter and quality of the access vessels, and at least
20 mm distance from the distal margin of the left common
carotid artery to the intimal disruption on center-of-ﬂow
imaging reconstructions
Exclusion criteria. Patients with the following condi-
tions were excluded from the RESCUE trial: planned
placement of the stent graft cloth over the left common
carotid artery (or the innominate artery in a case of a bovine
arch) or the celiac artery; evidence of systemic infection,
pregnancy, previous history of descending thoracic aortic
intervention or operation, history of bleeding diathesis,
coagulopathy, allergy to the device components, participa-
tion in conﬂicting investigational drug or device clinical
trials, known hypersensitivity or contraindication to antico-
agulants or contrast media that was not amenable to
pretreatment; nonsurvivable injury/condition of subject,
or a history of a cerebral vascular accident within the
2 preceding months. No speciﬁc Injury Severity Score
(ISS) constituted exclusion criteria.
Deﬁnitions. BTAI was classiﬁed as described by
Azizzadeh et al.3 Grade I injury was conﬁned to the
intima, grade II was conﬁned to the media and associated
with an intramural hematoma, grade III had a pseudoa-
neurysm, and grade IV represented frank aortic rupture
with blood inside the pleural cavity. Patients were also
graded using the ISS, an anatomic system that provides an
overall score for patients with multiple injuries.20
Follow-up. All survivors were entered into the
RESCUE trial follow-up protocol consisting of a physical
examination, adverse event evaluation, a CTA or magnetic
resonance angiogram at 1, 6, and 12 months and annually
thereafter for 5 years. Multiple view chest x-rays will also be
acquired at 1, 3, and 5 years to assess for device integrity.
Statistical analysis. Descriptive statistics were re-
ported for the study cohort using the Statistical Analysis
Software (SAS) v. 9.2 (SAS Institute, Cary, NC).RESULTS
Fifty patients were enrolled from 69 patients screened
at 20 centers, most of which were level I trauma centers.
The number of patients enrolled at each site ranged from
one to ﬁve. Reasons for screen failure included the
following: surgical treatment pursued (two); medical treat-
ment pursued (two); device of the appropriate size was not
available (four); unable to obtain informed consent (two);
patient died just after being consented (one); patient
declined to participate in study (one); insurance would
not cover (one); and six patients who did not meet inclu-
sion or exclusion criteria, including aortic diameter less
than 15 mm (one), proximal landing zone distance <20
mm (one), contraindication to anticoagulants (one),
patient was pregnant (one), patient had a nonsurvivable
injury or condition (one), and procedure occurred more
than 30 days after injury (one). All patients but one
completed 1-month follow-up, including one patient who
died within 30 days. No patient was lost to follow-up.
Table I. Demographics and medical history
Demographics
Age
Mean age 6 SD 41 6 17
Median age (range) 39.5 (18-76)
Male, % (m/n) 76% (38/50)
Ethnicity: Hispanic or Latino 20% (10/50)
Race
White 68% (34/50)
Black or African American 20% (10/50)
Asian 4% (2/50)
Other or not available 8% (4/50)
Medical history
Hypertension 24% (12/50)
Chronic obstructive pulmonary disease 4% (2/50)
Renal insufﬁciency 0% (0/50)
Congestive heart failure 2% (1/50)
Myocardial infarction 0% (0/50)
Coronary artery bypass grafting 0% (0/50)
Stroke/cerebrovascular accident 0% (0/50)
Paraplegia 2% (1/50)
Paraparesis 0% (0/50)
Bleeding disorder 0% (0/50
Diabetes 2% (1/50)
Gastrointestinal conditions 2% (1/50)
Other important medical condition 46% (23/50)
SD, Standard deviation.
Table II. Injury characteristics
Extent of overall injuries
Assigned injury severity score
Mean 6 SD 38 6 14
Median (range) 35 (13-75)
Extent of aortic injury
Grade I: intimal tear 18% (9/50)
Grade II: intramural hematoma 12% (6/50)
Grade III: aortic pseudoaneurysm 68% (34/50)
Grade IV: free rupture 2% (1/50)
Associated traumatic injuries
Head injury 48% (24/50)
Neurologic deﬁcits 12% (6/50)
Long B1 fracture 38% (19/50)
Pelvic fracture 40% (20/50)
Scapula fracture 8% (4/50)
Unstable C/T/L spine fractures 14% (7/50)
Abdominal injurya 58% (29/50)
Lung injury 70% (35/50)
Rib fracture 64% (32/50)
Sternum fracture 6% (3/50)
Other 50% (25/50)
SD, Standard deviation.
aSolid organ, bowel, bladder, or diaphragm injury.
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Mean age was 41 6 17 years (18-76). Seventy-six
percent (38/50) were male. Demographics and medical
history of the study group are shown in Table I. The
mean ISS was 38 6 14 (13-75). Motor vehicle collisions
accounted for most injuries (60%), followed by motorcycle
accidents (22%), pedestrian injury by vehicles (10%), falls
(4%), and other mechanisms (4%). Injury characteristics
are presented in Table II. The extent of aortic injury was
classiﬁed as grade I in 18% (9/50), grade II in 12% (6/
50), grade III in 68% (34/50), and grade IV in 2% (1/
50), respectively. Indications for intervention were BTAI
in the proximal descending thoracic aorta (aortic isthmus)
in 84% (42/50) and in the distal half of the descending
thoracic aorta in 16% (8/50). Anatomic characteristics are
presented in Table III. The mean diameter at the proximal
landing zone was 24.3 6 3.9 mm, with a range of 18 to
35 mm, whereas the mean diameter at the distal landing
zone was 22.5 6 4.1 mm with a range of 18 to 34 mm.
The mean maximum descending thoracic aorta diameter
was 26.5 6 6.6 with a range of 18 to 42 mm.
Procedural data
After the initial trauma survey, patients were stabilized,
evaluated for concomitant injury, and the timing of the
TEVAR was determined based on the discretion of the
operator and trauma surgeon. Fifty-one Medtronic Valiant
Captivia thoracic stent grafts (Medtronic, Inc) (Fig) and
a single Talent thoracic stent graft (Medtronic, Inc) were
implanted in the 50 patients within a median of 1.0 days
following injury (mean, 1.86 4.0; 0-23 days). Two patients
each received two stent grafts; one received a Talent stentgraft as a second device because of the emergent nature of
the case and the lack of availability of an appropriately sized
Valiant graft (Medtronic, Inc) at the site. All but one of the
stent grafts placed in the proximal position were proximal
bare spring conﬁgurations; a closed web tapered graft was
placed in the proximal position in one patient. Investigators
reported 100% delivery and deployment success of the stent
graft in this study population, and no ﬁnding of misaligned
deployment was made by the core laboratory. There were
no reports of aortic perforation, retrograde type A dissec-
tion, or conversions to open surgery.
All endovascular exclusions were performed under
general anesthesia using a ﬁxed ﬂuoroscopic imaging
system or C-arm in the operating room or an endovascular
suite. Ninety-eight percent (49/50) of patients received
stent grafts implanted via a femoral (46/50) or iliac
(3/50) approach by an open or percutaneous technique;
an aortic conduit was required in one patient. Systemic
heparinization was used in 80% (40/50) of patients prior
to introduction of the stent graft. Median blood loss was
50 mL (10-900). Median ﬂuoroscopy and operative times
were 8 minutes (3-66) and 91 minutes (35-311), respec-
tively. Median contrast material used was 110 mL
(31-230). Two patients had preoperative insertion of
a cerebrospinal ﬂuid drainage catheter. The left subclavian
artery was covered in 58% of patients (29/50), with
complete coverage in 20 and partial coverage in nine
patients. Fifty-four percent (28/52) of implanted Valiant
grafts were 26 mm or less in size (Fig). Mean oversizing
was 10%. Median intensive care unit stay and hospital
stay were 6 days (1-108) and 12 days (1-147), respectively.
Primary end point
The primary objective for this study was to assess the
safety of Valiant Captivia in subjects with BTAI determined
Table III. Anatomic characteristics (core laboratory
reported)
Category
Distance from left subclavian artery to injury
No. 50
Mean 6 SD, mm 15.0 6 9.4
Median (range), mm 13.5 (0-36)
Aortic diameter 20 mm proximal to injury
No. 50
Mean 6 SD, mm 24.3 6 3.9
Median (range), mm 23.5 (18-35)
Maximum descending thoracic artery diameter
No. 50
Mean 6 SD, mm 26.5 6 6.6
Median (range), mm 25.5 (18-42)
SD, Standard deviation.
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Fig. Distribution of stent graft diameters.
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30 days of the index procedure, resulting in an all-cause
30-day mortality rate of 8.0% (Table IV). Two of these
deaths (patients 018-001 and 059-002) were considered
by the CEC to be aortic-related. One of the two deaths
(patient 059-002) was adjudicated to be related to the
aortic injury, device, and procedure because of the ill-
deﬁned nature of the available data.
Early deaths
Patient 018-001. A 22-year-old male, thrown from
a horse into a tree, arrived with bilateral hemothoraces and
a myocardial contusion (ISS ¼ 30, grade III aortic injury).
The patient underwent prompt and successful TEVAR, with
the postprocedural aortogram demonstrating successful
exclusion of BTAI and no extravasation or endoleak. While
the left-sided hemothorax subsided after TEVAR, the
patient expired on the next day from continued right-sided
massive hemothorax. An autopsy was performed on this
patient and showed no evidence of an additional aortic
injury. The CEC adjudicated this death to be related to the
aortic injury and unrelated to the device or procedure.
Patient 182-001. A 68-year-old male blind pedestrian
was hit by a motorcycle and presented to the hospital
with a BTAI and several comorbidities including traumatic
brain injury (ISS ¼ 50, grade III aortic injury). The patient
underwent prompt and successful TEVAR but died
the next day from the brain injury. The CEC adjudicated
the death as unrelated to the aortic injury, device, or the
procedure.
Patient 344-033. A 23-year-old male in a motorcycle
accident presented to the hospital with a right hemop-
neumothorax, deformities in both legs, and multiple frac-
tures of the femur. (ISS ¼ 29, grade III aortic injury). The
patient underwent prompt and successful TEVAR and
expired on day 5 from cardiac arrhythmia. The death was
adjudicated by the CEC as unrelated to the aortic injury,
device, or procedure.
Patient 059-002. A 67-year-old female, with a history
of atrial ﬁbrillation and recent pulmonary embolus on
coumadin, was admitted after a motor vehicle accident
with a BTAI associated with distal dissection into theabdominal aorta, subarachnoid hemorrhage, T1 spinal
fracture, bilateral hemothoraces, liver laceration, and other
abdominal injuries (ISS ¼ 34, grade III aortic injury). She
underwent successful TEVAR exclusion with angiographic
documentation of no endoleaks and expected false lumen
perfusion in the abdominal aorta. Two subsequent CTAs
(including one performed 1 week prior to her demise)
revealed the stent graft to be in good position with no
endoleak and with formation of a hematoma in the false
lumen. One week after discharge to an acute care facility,
the patient experienced sudden unexplained death on day
22. The patient had a history of atrial ﬁbrillation and
subtherapeutic anticoagulation, however, because of the
lack of autopsy, the cause of death was undetermined.
Because of the ill-deﬁned nature of the relationship
between this patient’s death and the device, procedure, and
aortic injury and because of the limited information
available, the CEC conservatively adjudicated this death to
be related to all three.
Secondary end point results
The secondary end points of this trial were to evaluate
the safety and effectiveness of the device by assessing the
outcomes of the procedure and/or the occurrence of
device-, procedure- , or aortic-related adverse events and
aortic-related mortality within 30 days (Table V).
The 30-day CEC adjudicated aortic-related mortality
was 4.0% (2/50). In addition, six patients (12%) had seven
nonfatal procedure- and/or aortic-related adverse events
(Table VI) within 30 days. Other than the death of patient
059-002 (Table IV), there were no device-related adverse
events. The single nonfatal aortic-related adverse event is
discussed below under neurologic outcomes. Six other
patients had procedure-related adverse events within 30
days as listed in Table VI, including four access site compli-
cations and two cases of arm ischemia and claudication
requiring carotid-to-subclavian bypass. The two patients
with arm ischemia and claudication had partial and
complete coverage of the left subclavian artery, respec-
tively. After 30 days, two procedure-related adverse events
occurred, including one case of arm ischemia requiring
bypass. The other event involved a loss of radial pulse
Table IV. Early deaths
Patient
Time to
death, days
Cause of death site
reported
Death relatedness site
reported
Death relatedness adjudicated
by CEC ISS score
018-001 1 Hemothorax Not related Aortic injury related 30
182-001 1 Traumatic brain injury Not related Not related 50
344-033 5 Arrhythmia Not related Not related 29
059-002 22 Complications of multiple
blunt force injuries
Not related to procedure;
relatedness to device and aortic
injury not evaluable
Device related, procedure related,
aortic injury related
34
CEC, Clinical Events Committee; ISS, Injury Severity Score.
Table V. Study end points
Primary end point
All-cause mortality (30 days) 8% (4/50)
Secondary end points
Procedure- and/or aortic injury-related
adverse events (30 days)
12% (6/50)
Aortic injury-related mortality (30 days) 4% (2/50)
Technical success
Successful delivery and deployment
of the stent graft
100% (50/50)
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of radial pulse had intentional complete coverage of the
left subclavian artery.
Endoleaks and reinterventions
The core laboratory reviewed the intra- and postoper-
ative imaging of all enrolled patients, ﬁnding no endoleaks.
Furthermore, no stent graft migration, kinking, twisting,
fracture, or loss of stent graft integrity or patency was
observed. No secondary endovascular reintervention or
conversion to open surgery occurred.
Neurologic outcomes
Upon admission, six (12%) patients had neurologic
deﬁcit attributable to associated head injury. One patient
presented with preoperative paraplegia. No patient had
a preprocedural history of stroke.
There were no cases of spinal cord injury or embolic
stroke related to the TEVAR procedure. One patient
experienced aortic rupture with free extravasation during
the procedure prior to device introduction (340-004).
The stent graft successfully excluded the grade IV aortic
injury with planned partial coverage of the left subclavian
artery; however, the patient suffered anoxic brain injury
attributable to the periprocedural hypotensive state.
The anoxic brain injury was considered as an aortic-related
adverse event. The patient was discharged to home, and in
the follow-up period beyond 30 days, developed bowel
ischemia secondary to extended bowel obstruction and
expired on day 169 because of an infection.
DISCUSSION
Since the introduction of commercially available stent
grafts in 2005, TEVAR has been increasingly used asa primary treatment option for BTAI. TEVAR has shown
signiﬁcant promise and efﬁcacy in various studies.3,6-18,21
In 2008, the American Association for the Surgery of
Trauma (AAST) reported on a prospective multicenter trial
evaluating the management of BTAI, conﬁrming the
increased utilization of TEVAR as the primary approach in
up to 65% of patients.14 In comparison to earlier reports
of results within open surgery, the same authors found
a signiﬁcant reduction in the early operative mortality rates
from 22% with open surgery to 13% using TEVAR, as well
as a reduction in spinal cord injury from 8.7% with open
surgery to 1.6% using TEVAR.15 While timing improved
by delaying the repair of BTAI and advancements in open
surgical techniques such as distal aortic perfusion have
contributed to improved BTAI outcomes overall, TEVAR
was clearly instrumental in reducing morbidity and mortality
in this complex patient cohort. These improved outcomes
have contributed to a paradigm shift from open surgery
toward off-label use of TEVAR in BTAI treatment, whether
as a bridge or for deﬁnitive treatment.
The RESCUE trial prospectively investigated the
outcomes of TEVAR in multiple centers using the
Medtronic Valiant Captivia stent graft (Medtronic, Inc) in
patients with BTAI to support potential FDA approval for
BTAI indications. RESCUE was designed as a descriptive
study focused on safety outcomes. The primary end point
of the RESCUE trial was 30-day all-cause mortality and
was shown to be 8.0% (4/50). This result is within the
expected mortality rate of 0%-15% as reported in the
literature3,7,9,11,13,14 and compares favorably to the 13%
mortality rate reported in the 2008 AAST2 study.15 It is
noteworthy that RESCUE was a purely TEVAR trial, while
theAAST2 cohort consisted of patients treated by both open
and endovascular techniques. Moreover, the RESCUE
investigators were selected from high-volume centers expe-
rienced in TEVAR, having surpassed the learning curve,
while some groups included in the AAST report may have
been relatively new to the technology. Recent clinical prac-
tice guidelines purely based on TEVAR studies for BTAI
quote mortality rates of approximately 9%.18,22
The secondary end points were the safety and effective-
ness of the device as assessed by the incidence of nonfatal
adverse events within 30 days related to the device, proce-
dure or aorta, and aortic-related mortality. By these criteria,
the Medtronic Valiant Captivia (Medtronic, Inc) was
shown to be a safe device. Although one death was
Table VI. Detail on adverse events (excluding those in Table IV that led to a death within 30 days)
Patient Adverse event
Days after
procedure Serious?
Related to device,
procedure, or
aortic injury? Action taken
Adverse events # 30 days, related to the device, procedure, or aortic injury
005-003 Focal dissection of the
common femoral artery
0 Yes Procedure Thrombectomy and Dacron patch
340-001 Hematoma 0 No Procedure None
340-004 Anoxic brain injury
(rupture just prior to procedure)
0 Yes Aortic injury Initial stent graft placement
340-004 Iliac vein laceration 0 Yes Procedure Surgical repair
325-003 Erythema at groin incision 4 No Procedure Medication
325-002 Peripheral ischemia 7 Yes Procedure Carotid-to-subclavian bypass
112-004 Arm claudication 30 Yes Procedure Carotid-to-subclavian bypass
Additional serious adverse events > 30 days, reported to date, related to the device, procedure, or aortic injury
344-002 Upper limb ischemia 36 Yes Procedure Carotid-to-subclavian bypass
325-003 Lack of palpable pulse in arm 39 No Procedure None
340-004 Bowel infection (leading to
death at 169 days)
167 Yes Unrelated None
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the conservative approach stemmed from little or no infor-
mation being available about the cause of death. There
were no nonfatal device-related adverse events and 100%
delivery and deployment success was achieved. The latter
observation is particularly noteworthy given the younger
age of patients with BTAI and the challenges associated
with the narrow radius of curvature of the aortic arch,
the severe angulation seen in zones II and III, the hyperdy-
namic hemodynamics, and the signiﬁcant variations in
the intravascular volume status and the small diameters of
the thoracic aorta predisposing to stent graft oversizing
and collapse in this patient population.12,23
Twelve percent (6/50) of patients enrolled in
RESCUE experienced seven nonfatal adverse events within
30 days. Six of the seven events were procedure-related,
four of which access vessel-related, including surgical
site hematoma, erythema, iliac vein laceration, and femoral
artery dissection, the latter two requiring local vascular
repair. Another two patients developed arm ischemia
and claudication within 30 days (and one-third developed
similar symptoms at day 36), an expected delayed compli-
cation associated with partial or complete coverage of the
left subclavian artery, which was performed in 58%
(29/50). This result is commensurate with recent reports
of 41%24 and 61%25 left subclavian arterial coverage.
One patient had an aortic-related adverse event,
anoxic brain injury because of prolongedperioperative hypo-
tension attributable to the development of active aortic
hemorrhage during the induction of general anesthesia at
the time of the procedure. Otherwise, there were no new
neurologic events compared with an incidence of paraplegia
rates seen with open surgical repair as high as 19%.26
Patients with an aortic transection usually have a high
incidence of associated chest trauma, which can nega-
tively impact the performance of a left-sided thora-
cotomy. During an open aortic repair procedure, the
left lung has to be deﬂated requiring the patient to relyentirely on the right lung for oxygenation, or, alterna-
tively, necessitates that the patient be placed on cardio-
pulmonary bypass. Furthermore, in case of signiﬁcant
left-sided rib fracture and associated pulmonary contu-
sion, avoidance of a thoracotomy can result in decreased
pulmonary complications. The latter advantage has been
described in TEVAR procedures performed in patients
with thoracic aneurysms or aortic dissections and associ-
ated pulmonary disease.
Limitations of this study include the lack of randomiza-
tion of patients, the short period of follow-up to date,
and the selection of institutions experienced with
TEVAR. However, further follow-up is in progress
and will be reported when the data become available.
Since longer-term safety and effectiveness of TEVAR is
well-established in the treatment of aneurysms, this article
focuses on the primary end point of the trial (ie, 30-day
mortality associated with the treatment of BTAI).
It may also be somewhat controversial that TEVAR
treatment was selected for the 18% of patients in this study
with grade I aortic injury. The decision to enroll these
subjects in the RESCUE trial was made by the on-site
investigators and the corresponding trauma surgeons
according to their considerable experience with such
patients. Although there are controversies whether this
group of patients may be managed watchfully with serial
imaging, many physicians prefer early TEVAR in patients
with concomitant head injuries, allowing early elevation
of systemic and cerebral perfusion pressures with vasopres-
sors. In RESCUE, the decision to treat subjects with grade
I aortic injuries was because of uncertainty regarding
progression of the injury based on serial imaging and
the presence of either hypotension with dropping blood
pressure, long intimal tears, or competing injuries.
CONCLUSIONS
TEVAR using the Medtronic Valiant Captivia (Med-
tronic, Inc) was a safe and effective approach for primary
JOURNAL OF VASCULAR SURGERY
Volume 57, Number 4 Khoynezhad et al 905treatment of BTAI. Both primary and secondary end points
of RESCUE compare favorably to the body of literature on
BTAI. Long-term follow-up will be required to determine
the effectiveness and longevity of stent grafts in this complex
patient population.
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Appendix (online only). RESCUE investigators
Principal investigator Site City
Patients
enrolled
Rodney A. White, MD Harbor UCLA Torrance, Calif 5
Ali Azizzadeh, MD Memorial Hermann Heart and Vascular Institute Houston, Tex 5
Alan H. Matsumoto, MD University of Virginia Medical Center Charlottesville, Va 5
Omaida C. Velazquez, MD University of Miami Jackson Memorial Hospital Miami, Fla 4
Joshua Rovin, MD Cardiac Surgical Associates Bayfront Medical Center St. Petersberg, Fla 3
Joseph V. Lombardi, MD Cooper Health System Camden, NJ 3
Ernest Moore, MD
Robert Allen, MD
Denver Heath Denver, Colo 3
Robert Hieb, MD Medical College of Wisconsin Froedtert Hospital Milwaukee, Wisc 3
Bart E. Muhs, MD Yale New Haven Hospital New Haven, Conn 3
G. Chad Hughes, MD Duke University Medical Center Durham, NC 2
Francios Dagenais, MD Institut Universitaire de Cardiologie et de Pneumologie de Québec Québec, QC 2
Himanshu J. Patel, MD Regents of the University of Michigan Ann Arbor, Mich 2
Clifford J. Buckley, MD Scott and White Memorial Hospital Temple, Tex 2
Robert J. Feezor, MD University of Florida Gainesville, Fla 2
Marc L. Schermerhorn, MD Boston, Mass Boston, Mass 1
Ali Khoynezhad. MD Cedars Sinai Medical Center Los Angeles, Calif 1
JeanM, Panneton, MD Sentara Norfolk General Vascular & Transplant Specialists Norfolk, Va 1
John P. Pigott, MD Toledo Hospital Jobst Vascular Center Toledo, Ohio 1
William D. Jordan, MD University of Alabama Hospital Birmingham, Ala 1
Nirman Tulsyan, MD Vascular Research Institute Morristown Memorial Morristown, NJ 1
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